Amphastar Pharmaceuticals (AMPH) Income from Non-Controlling Interests (2018 - 2021)

Amphastar Pharmaceuticals has reported Income from Non-Controlling Interests for 4 years, with the latest figure at $1.4 million in Q3 2021.

• On a quarterly basis, Income from Non-Controlling Interests rose 261.56% year-over-year to $1.4 million in Q3 2021; TTM through Dec 2021 was $1.6 million, a 12.82% decrease from a year earlier, with the FY2025 full-year figure at -$57000.0, changed N/A from the prior year.
• Income from Non-Controlling Interests was $1.4 million for Q3 2021 at Amphastar Pharmaceuticals, up from -$855000.0 in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $3.0 million in Q1 2019, with the low at -$874000.0 in Q3 2020.
• Average Income from Non-Controlling Interests over 4 years is $802846.2, with a median of $1.1 million recorded in 2021.
• The sharpest annual moves came in 2020 and 2021: Income from Non-Controlling Interests plunged 368.1% in 2020, then surged 261.56% in 2021.
• Over 4 years, Income from Non-Controlling Interests stood at $1.7 million in 2018, then gained by 5.07% to $1.8 million in 2019, then tumbled by 38.63% to $1.1 million in 2020, then gained by 29.19% to $1.4 million in 2021.
• The last three Income from Non-Controlling Interests figures came in at $1.4 million (Q3 2021), -$855000.0 (Q2 2021), and $1.1 million (Q1 2021), per Business Quant data.